Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Biosergen AS (BIOSGN) - Total Liabilities
Latest total liabilities as of December 2025: Skr13.04 Million SEK
Based on the latest financial reports, Biosergen AS (BIOSGN) has total liabilities worth Skr13.04 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biosergen AS - Total Liabilities Trend (2019–2025)
This chart illustrates how Biosergen AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biosergen AS Competitors by Total Liabilities
The table below lists competitors of Biosergen AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CIENA - Dusseldorf Stock Exchang
DU:CIE1
|
Germany | €2.68 Billion |
|
Callan JMB Inc. Common Stock
NASDAQ:CJMB
|
USA | $3.56 Million |
|
Charn Issara Development Public Company Limited
BK:CI
|
Thailand | ฿8.16 Billion |
|
Zenith Exports Limited
NSE:ZENITHEXPO
|
India | ₹130.70 Million |
|
Computer Direct
TA:CMDR
|
Israel | ILA1.47 Billion |
|
City Office
NYSE:CIO
|
USA | $456.78 Million |
|
CREDICORP (D8V.SG)
STU:D8V
|
Germany | €215.04 Billion |
|
NOVA MEASURING INTR
BE:NMR
|
Germany | €426.11 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Biosergen AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biosergen AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biosergen AS (2019–2025)
The table below shows the annual total liabilities of Biosergen AS from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr13.04 Million | +251.55% |
| 2024-12-31 | Skr3.71 Million | -27.06% |
| 2023-12-31 | Skr5.08 Million | -53.76% |
| 2022-12-31 | Skr11.00 Million | +18.84% |
| 2021-12-31 | Skr9.25 Million | -41.14% |
| 2020-12-31 | Skr15.72 Million | +38.26% |
| 2019-12-31 | Skr11.37 Million | -- |